Product Comparison


  Sanofi Pasteur 49281051925 Seqirus USA Inc 70461041910 Seqirus USA Inc 70461031903 Seqirus USA Inc 33332041910 Sanofi Pasteur 49281040565
McKesson # 1120531 1121575 1121577 1121562 1120529
Description Fluzone® Quadrivalent 2019 - 2020 Pediatric Flu Vaccine 30 mcg / 0.25 mL Indicated For People 6 Months to 35 Months of Age Prefilled Syringe 0.25 mL Flucelvax® Quadrivalent 2019 - 2020 Flu Vaccine 60 mcg / 0.5 mL Indicated For People 4 Years of Age and Above Multiple Dose Vial 5 mL Flucelvax® Quadrivalent 2019 - 2020 Flu Vaccine 60 mcg / 0.5 mL Indicated For People 4 Years of Age and Above Prefilled Syringe 0.5 mL Afluria® Quadrivalent 2019 - 2020 Flu Vaccine 60 mcg / 0.5 mL Indicated for People 6 Months of Age and Above Multiple Dose Vial 5 mL Fluzone® High-Dose 2019 - 2020 Flu Vaccine 180 mcg / 0.5 mL Indicated For People 65 Years of Age and Above Prefilled Syringe 0.5 mL
Manufacturer # 4928105192570461041910704610319033333204191049281040565
Brand Fluzone® Quadrivalent 2019 - 2020 PediatricFlucelvax® Quadrivalent 2019 - 2020Flucelvax® Quadrivalent 2019 - 2020Afluria® Quadrivalent 2019 - 2020Fluzone® High-Dose 2019 - 2020
Manufacturer Sanofi PasteurSeqirus USA IncSeqirus USA IncSeqirus USA IncSanofi Pasteur
Invoice FLUZONE 2019 QUAD, SYR 0.25ML PED (10DOSE/BX)FLUCELVAX 2019, QUAD MDV 5ML (10DOSE/VL)FLUCELVAX 2019, QUAD SYR 0.5ML(10DOSE/BX)AFLURIA 2019, QUAD MDV 5ML (10DOSE/VL)FLUZONE 2019, PFS HIGH DOSE 0.5ML (10DOSE/BX)
    Log In to Order   Log In to Order   Log In to Order   Log In to Order   Log In to Order

Comparison

Container Type Prefilled SyringeMultiple Dose VialPrefilled SyringeMultiple Dose VialPrefilled Syringe
Country of Origin UnknownUnited StatesUnited StatesAustraliaUnknown
NDC Number 4928105192570461041910704610319033333204191049281040565
Strength 30 mcg / 0.25 mL60 mcg / 0.5 mL60 mcg / 0.5 mL60 mcg / 0.5 mL180 mcg / 0.5 mL
User Indicated For People 6 Months to 35 Months of AgeIndicated For People 4 Years of Age and AboveIndicated For People 4 Years of Age and AboveIndicated For People 6 Months of Age and AboveIndicated For People 65 Years of Age and Above
Volume 0.25 mL5 mL0.5 mL5 mL0.5 mL
Application Flu VaccineFlu VaccineFlu VaccineFlu VaccineFlu Vaccine
Dosage Form InjectionInjectionInjectionInjectionInjection
Product Dating McKesson Acceptable Dating: we will ship >= 30 daysMcKesson Acceptable Dating: we will ship >= 30 daysMcKesson Acceptable Dating: we will ship >= 30 daysMcKesson Acceptable Dating: we will ship >= 30 daysMcKesson Acceptable Dating: we will ship >= 30 days
Storage Requirements Requires RefrigerationRequires RefrigerationRequires RefrigerationRequires RefrigerationRequires Refrigeration
Type IntramuscularIntramuscularIntramuscularIntramuscularIntramuscular
UNSPSC Code 5120160851201608512016085120160851201608
Features and Benefits
  • Fluzone® Quadrivalent is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine
  • Fluzone Quadrivalent is approved for use in persons 6 months of age and older
  • The single-dose, pre-filled syringe (0.25 mL and 0.5 mL) and the single-dose vial (0.5 mL) are manufactured and formulated without thimerosal or any other preservative
  • Fluzone Quadrivalent is standardized according to United States Public Health Service requirements and is formulated to contain HA of each of the following four influenza strains recommended for the 2019-2020 influenza season: A/Brisbane/02/2018 IVR-190 (H1N1), A/Kansas/14/2017 X-327 (H3N2), B/Phuket/3073/2013 (B Yamagata lineage), and B/Maryland/15/2016 BX-69A (a B/Colorado/6/2017-like virus, B Victoria lineage).
  • FLUCELVAX QUADRIVALENT is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine
  • FLUCELVAX is approved for use in persons 4 years of age and older
  • FLUCELVAX QUADRIVALENT 5 mL multi-dose vial formulation contains no antibiotics
  • FLUCELVAX QUADRIVALENT is standardized according to United States Public Health Service requirements for the 2019-2020 influenza season and is formulated to contain a total of 60 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA of each of the following four influenza strains:
  • A/Idaho/07/2018 (an A/Brisbane/02/2018 (H1N1)pdm09-like virus), A/Indiana/08/2018 (an A/Kansas/14/2017 (H3N2)-like virus), B/Iowa/06/2017 (a B/Colorado/06/2017-like virus), B/Singapore/INFTT-16-0610/2016 (a B/Phuket/3073/2013-like virus)
  • FLUCELVAX QUADRIVALENT is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine
  • FLUCELVAX is approved for use in persons 4 years of age and older
  • FLUCELVAX QUADRIVALENT 0.5 mL pre-filled syringes contain no preservative or antibiotics
  • FLUCELVAX QUADRIVALENT is standardized according to United States Public Health Service requirements for the 2019-2020 influenza season and is formulated to contain a total of 60 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA of each of the following four influenza strains:
  • A/Idaho/07/2018 (an A/Brisbane/02/2018 (H1N1)pdm09-like virus), A/Indiana/08/2018 (an A/Kansas/14/2017 (H3N2)-like virus), B/Iowa/06/2017 (a B/Colorado/06/2017-like virus), B/Singapore/INFTT-16-0610/2016 (a B/Phuket/3073/2013-like virus)
  • AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine
  • AFLURIA QUADRIVALENT is approved for use in persons 6 Months and older
  • The multi-dose presentation contains thimerosal added as a preservative; each 0.5 mL dose contains 24.5 mcg of mercury
  • AFLURIA QUADRIVALENT is standardized according to USPHS requirements for the 2019-2020 influenza season and is formulated to contain 60 mcg hemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 mcg HA for each of the four influenza strains recommended for the 2019-2020 Northern Hemisphere influenza season:
  • A/Brisbane/02/2018 (IVR-190) (an A/Brisbane/02/2018 (H1N1)pdm09 – like virus), A/Kansas/14/2017 (X-327) (an A/Kansas/14/2017 (H3N2) – like virus), B/Maryland/15/2016 (a B/Colorado/06/2017 – like virus) and B/Phuket/3073/2013 BVR-1B (a B/Phuket/3073/2013 – like virus). A 0.25 mL dose contains 7.5 mcg HA of each of the same four influenza strains.
  • Fluzone High-Dose is a vaccine indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B virus contained in the vaccine
  • Fluzone High-Dose is indicated for active immunization in persons 65 years of age and older
  • Fluzone High-Dose is standardized according to United States Public Health Service requirements and is formulated to contain HA of each of the following three influenza strains recommended for the 2019-2020 influenza season: A/Brisbane/02/2018 IVR-190 (H1N1), A/Kansas/14/2017 X-327 (H3N2), and B/Maryland/15/2016 BX-69A (a B/Colorado/6/2017-like virus, B Victoria lineage).